Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions and Methods for Preparing and Using Same

The present invention relates to a form 1 and form 2 polymorph of (-)-trans-3-(5,6 dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione. The present invention also relates to (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl) 4-(1H-indol-3-yl) pyrrolidine-2...

Full description

Saved in:
Bibliographic Details
Main Authors KANE, JOHN C, REED, DAVID P, BARNES, NEIL R, CHEN, JIAN-XIE, LEE, CHRISTOPHER A, REDMON, MARTIN P
Format Patent
LanguageEnglish
Published 05.11.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a form 1 and form 2 polymorph of (-)-trans-3-(5,6 dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione. The present invention also relates to (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl) 4-(1H-indol-3-yl) pyrrolidine-2, 5-dione compounds having a chiral purity greater than 99%, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising these (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(lH-indol-3-yl) pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a composition comprising (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione having a chiral purity greater than 99% or a form 1 and form 2 polymorph of (-) trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5 dione.
Bibliography:Application Number: AU20150243015